Valuation: Ipca Laboratories Limited

Market Cap 505B 5.29B 4.62B 4.34B 3.96B 7.44B 7.44B 52.12B 20.11B 258B 19.86B 19.42B 832B P/E 2027 *
33.3x
P/E 2028 * 28.5x
Enterprise Value 495B 5.18B 4.52B 4.25B 3.88B 7.28B 7.28B 51.02B 19.69B 253B 19.44B 19.01B 815B EV / Sales 2027 *
4.5x
EV / Sales 2028 * 3.96x
Free-Float
54.94%
Yield 2027 *
0.29%
Yield 2028 * 0.31%
1 day-0.79%
1 week+1.15%
Current month+0.87%
1 month+4.28%
3 months+25.76%
6 months+28.78%
Current year+39.90%
1 week 1,906.85
Extreme 1906.85
2,039.3
1 month 1,896.85
Extreme 1896.85
2,039.3
Current year 1,392
Extreme 1392
2,039.3
1 year 1,252.95
Extreme 1252.95
2,039.3
3 years 886
Extreme 886
2,039.3
5 years 670
Extreme 670
2,039.3
10 years 200
Extreme 200
2,039.3
Manager TitleAgeSince
Chief Executive Officer 53 01/04/2023
Chief Executive Officer 70 01/04/2023
Chief Tech/Sci/R&D Officer 52 16/10/2023
Director TitleAgeSince
Chairman 79 05/07/2012
Director/Board Member 53 11/11/2008
Director/Board Member 70 01/08/1994
Change 5-day change 1-year change 3-year change Capi.($)
-0.79%+1.15% - - 5.32B
+0.69%+3.45%+55.68%+113.48% 1,038B
-0.12%+0.89%+54.75%+67.97% 649B
+0.39%+1.05%+19.42%+74.03% 467B
-0.19%+0.97%+34.30%+45.99% 355B
+0.28%+2.30%+18.47%+26.67% 269B
+0.89%+4.59%+10.19%+14.72% 260B
+3.65%+9.16%+43.38%+53.18% 213B
-0.46%-6.20%-32.46%-59.65% 176B
+0.79%+4.43%+35.81%+103.67% 187B
Average +0.52%+1.04%+26.62%+48.90% 401.68B
Weighted average by Cap. +0.53%+1.47%+36.63%+67.50%

Financials

2027 *2028 *
Net sales 110B 1.15B 1.01B 945M 862M 1.62B 1.62B 11.34B 4.38B 56.15B 4.32B 4.22B 181B 123B 1.28B 1.12B 1.05B 962M 1.8B 1.81B 12.65B 4.88B 62.64B 4.82B 4.71B 202B
Net income 15.15B 158M 138M 130M 119M 223M 223M 1.56B 603M 7.73B 595M 582M 24.93B 17.8B 186M 163M 153M 140M 262M 262M 1.84B 708M 9.09B 699M 684M 29.3B
Net Debt -10.65B -111M -97.36M -91.5M -83.5M -157M -157M -1.1B -424M -5.44B -418M -409M -17.53B -19.96B -209M -182M -171M -156M -294M -294M -2.06B -794M -10.19B -784M -767M -32.85B
Logo Ipca Laboratories Limited
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The Company’s products are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc. and Ipca Pharma Nigeria Ltd.
Employees
17,210
Date Price Change Volume
22/09/26 INR 1,992.20 -0.79% 5,828
21/09/26 INR 2,008.05 -0.15% 10,576
18/09/26 INR 2,011.00 +2.09% 50,010
17/09/26 INR 1,969.80 +1.02% 21,176
16/09/26 INR 1,949.85 +0.80% 16,885
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
1,992.40INR
Average target price
1,972.28INR
Spread / Average Target
-1.01%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!